Tag Archive for: cervical cancer

HPV-immunisation-in-UK-lowers-the-incidence-of-cervical-cancer-and-CIN3

HPV immunisation in UK lowers the incidence of cervical cancer and CIN3

Human papillomavirus (HPV) can cause cervical cancer, anogenital cancers and head and neck cancers if long-lasting infections are triggered by high-risk HPV strains, accounting for the great burden of HPV-related cancers worldwide with an estimated incidence in 570,000 women and 600,000 men each year.

KEYNOTE-158-pembrolizumab-in-previously-treated-advanced-cervical-cancer

KEYNOTE-158: pembrolizumab in previously treated advanced cervical cancer

Immunotherapy with programmed death 1 (PD-1) antibody pembrolizumab led to an objective response rate (ORR) of 14.6% in previously treated advanced cervical cancer patients with PD-L1–positive disease, as reported by Chung et al. on behalf of the KEYNOTE-158 investigators in the Journal of Clinical Oncology.

FDA approved pembrolizumab for chemotherapy-refractory r/m cervical cancer with PD-L1 CPS ≥1 

 

  • On June 12, 2018 the FDA approved pembrolizumab (KeytrudaⓇ, Merck & Co. Inc.) for patients with chemotherapy-refractory recurrent or metastatic (r/m) cervical cancer and with a combined positive score (CPS)≥1 PD-L1 level expression.